XOMA Royalty Completes Tender Offer for HilleVax, Acquiring 77.48% of Shares.

XOMA Royalty Corporation has successfully completed its tender offer to acquire all outstanding shares of HilleVax common stock for a price of $1.95 in cash, plus a non-tradeable contingent value right. A total of 39,214,689 shares were validly tendered, representing approximately 77.48% of the outstanding shares of HilleVax common stock. The transaction is expected to enhance XOMA Royalty's portfolio of biotechnology assets.

XOMA Royalty Corporation has successfully completed its tender offer to acquire all outstanding shares of HilleVax common stock for a price of $1.95 in cash, plus a non-tradeable contingent value right. A total of 39,214,689 shares were validly tendered, representing approximately 77.48% of the outstanding shares of HilleVax common stock. The transaction is expected to enhance XOMA Royalty's portfolio of biotechnology assets REG - Irish Takeover Panel - Disclosure Table^[1].

The acquisition was announced on September 12, 2025, and the tender offer period commenced on April 15, 2025. The offer was made by XOMA Royalty Corporation, and the dealings and positions in the offeror were not required to be disclosed REG - Irish Takeover Panel - Disclosure Table^[1].

The transaction is subject to customary closing conditions, including the receipt of necessary regulatory approvals. The completion of the acquisition is expected to provide XOMA Royalty Corporation with access to HilleVax's proprietary technology and intellectual property, further strengthening its position in the biotechnology sector.